Radiation Therapy Concurrent with Weekly Paclitaxel for Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of a Phase I Trial.
M Chen,SX Wu,YY Chen,LX Lu,Y Bao,HX Lin,CG Xian,Q Li,XW Deng,TX Lu,NJ Cui
DOI: https://doi.org/10.1097/01.coc.0000135180.94470.45
2004-01-01
American Journal of Clinical Oncology
Abstract:Purpose: The purpose of this study was to define the maximum tolerated dose (MTD) by describing the dose-limiting toxicity (DLT) of paclitaxel given as a 3-hour intravenous infusion concurrently with conventional radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Materials and Methods: Patients with locoregionally advanced NPC were enrolled into a dose-escalating study. Toxicity was graded according to Common Toxicity Criteria 2.0. MTD was defined when 2 of 6 patients developed DLT. The starting dose of paclitaxel was 20 mg/m(2) once weekly, with a subsequent dose mg/m(2) escalation of 10 mg/m(2) in cohorts of 3 new patients. Radiation therapy was administered in a conventional technique over 7 weeks in 2.0-Gy/daily fractions for 5 days/wk up to total doses of 68-70 Gy. Results: From November 2000 to June 2001, 16 patients completed chemoradiotherapy. On the first-dose level (20 mg/m(2)), no patient experienced DLT. On the next dose level with 30 mg/m(2), I patient experienced DLT with grade 3 mucositis, which lasted for 5 weeks, and among the additional 3 patients, no one developed DLT. On the third dose level with 40 mg/m(2), I patient developed grade 3 mucositis and another grade 3 dermatitis, and both of them lasted more than 3 weeks. To make the trial more credible, another 4 patients were added to the 30-mg/m(2) level, and no DLT occurred. Thus, the accrual of patients stopped. Conclusion: Combined modality with paclitaxel given weekly, as a 3-hour infusion concomitant to conventional radiotherapy, is feasible for locoregionally advanced NPC. The dose recommended for a phase 11 trial is 30 mg/m(2) with mucositis and dermatitis as DLT, and other toxicity is mild.Purpose: The purpose of this study was to define the maximum tolerated dose (MTD) by describing the dose-limiting toxicity (DLT) of paclitaxel given as a 3-hour intravenous infusion concurrently with conventional radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Materials and Methods: Patients with locoregionally advanced NPC were enrolled into a dose-escalating study. Toxicity was graded according to Common Toxicity Criteria 2.0. MTD was defined when 2 of 6 patients developed DLT. The starting dose of paclitaxel was 20 mg/m(2) once weekly, with a subsequent dose mg/m(2) escalation of 10 mg/m(2) in cohorts of 3 new patients. Radiation therapy was administered in a conventional technique over 7 weeks in 2.0-Gy/ daily fractions for 5 days/wk up to total doses of 68-70 Gy. Results: From November 2000 to June 2001, 16 patients completed chemoradiotherapy. On the first-dose level (20 mg/m(2)), no patient experienced DLT. On the next dose level with 30 mg/m(2), I patient experienced DLT with grade 3 mucositis, which lasted for 5 weeks, and among the additional 3 patients, no one developed DLT. On the third dose level with 40 mg/m(2), I patient developed grade 3 mucositis and another grade 3 dermatitis, and both of them lasted more than 3 weeks. To make the trial more credible, another 4 patients were added to the 30-mg/m(2) level, and no DLT occurred. Thus, the accrual of patients stopped. Conclusion: Combined modality with paclitaxel given weekly, as a 3-hour infusion concomitant to conventional radiotherapy, is feasible for locoregionally advanced NPC. The dose recommended for a phase 11 trial is 30 mg/m(2) with mucositis and dermatitis as DLT, and other toxicity is mild.additional theoretical benefit of this approach is to increase locoregional control through the interaction of the 2 modalities, which is not the case when they are administrated sequentially. An immediate disadvantage is that toxicity is also increased and suboptimal doses of both modalities are often mandatory. A phase I trial of a single agent of paclitaxel with concurrent radiotherapy was first performed in nonsmall cell lung cancer by Choy. 12 The paclitaxel was administered weekly over 3 hours for 6 weeks with daily radiation. The MTD was 60 Mg/M2 with the esophagitis as the principal DLT. Tishler et al. 13 reported that paclitaxel can be given on a 3 -week schedule at 100 Mg/M2 concurrent with radiation for head and neck cancer, and the preliminary results indicated good local control and acceptable toxicity. Until now, there was only I phase I trial of weekly paclitaxel with concurrent radiotherapy for head and neck carcinoma, and the RPTD was 30 Mg/M2, which was the same as the result of the study presented here. 14 In the present study, mucositis and dermatitis were the principal toxicities. Hematologic toxicity is dose limiting for many concurrent chemoradiation trials. In contrast, hematologic toxicity was very mild in this trial; only I patient developed grade 2 neutropenia. An unexpected finding was lymphopenia occurred in all patients accrued, which could be caused by the toxicity of paclitaxel or dexamethasone that was given weekly. Its clinical and prognostic significance awaits further study. Although it has been shown that paclitaxel has radio sensitizing effects in tumor cells, it has not been proven that paclitaxel potentates the reaction of normal tissues toward radiation. It has been described that stem cells of the normal jejunal mucosa in mice were not radiosensitized by paclitaxel, although additive toxicity was observed with higher drug doses. 15 In the present trial, the acute toxicities were acceptable; supporting paclitaxel did not have radiosensitizing effects to normal tissues when used as a radiosensitizer to tumors. The RPTD of 30 mg/m 2 is comparably low. However, it has been observed in vitro that the greatest radio sensitization is achieved with relatively low concentrations and long exposure times. In the study by Choy et al., HL-60 cells after I-hour exposure at 30 nM, the sensitized enhancement ratio was increased to 1.5. 15 So it isPurpose: The purpose of this study was to define the maximum tolerated dose (MTD) by describing the dose-limiting toxicity (DLT) of paclitaxel given as a 3-hour intravenous infusion concurrently with conventional radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).Materials and Methods: Patients with locoregionally advanced NPC were enrolled into a dose-escalating study. Toxicity was graded according to Common Toxicity Criteria 2.0. MTD was defined when 2 of 6 patients developed DLT. The starting dose of paclitaxel was 20 mg/m(2) once weekly, with a subsequent dose mg/m(2) escalation of 10 mg/m(2) in cohorts of 3 new patients. Radiation therapy was administered in a conventional technique over 7 weeks in 2.0-Gy/ daily fractions for 5 days/wk up to total doses of 68-70 Gy.Results: From November 2000 to June 2001, 16 patients completed chemoradiotherapy. On the first-dose level (20 mg/m(2)), no patient experienced DLT. On the next dose level with 30 mg/m(2), 1 patient experienced DLT with grade 3 mucositis, which lasted for 5 weeks, and among the additional 3 patients, no one developed DLT. On the third dose level with 40 mg/m(2), 1 patient developed grade 3 mucositis and another grade 3 dermatitis, and both of them lasted more than 3 weeks. To make the trial more credible, another 4 patients were added to the 30-mg/m(2) level, and no DLT occurred. Thus, the accrual of patients stopped.Conclusion: Combined modality with paclitaxel given weekly, as a 3-hour infusion concomitant to conventional radiotherapy, is feasible for locoregionally advanced NPC. The dose recommended for a phase II trial is 30 mg/m(2) with mucositis and dermatitis as DLT, and other toxicity is mild.